Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer

  • Technology appraisal guidance
  • TA310
  • Published: 
Download (PDF)

Why has NICE said this?

Afatinib was recommended because it works as well and costs about the same as other treatments available on the NHS.

NICE looks at how well treatments work in relation to how much they cost compared with other treatments available on the NHS.

  • Information Standard